Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2025-04-21 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关联方占用资金情况专项报告
Audit Report / Information Classification · 95% confidence The document is a specialized report titled "厦门艾德生物医药科技股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 2024 年度" which translates to a special report on non-operating fund occupation and other related party fund transactions for the year 2024. It includes detailed financial data about related party transactions and fund usage, audited by a registered accounting firm, with references to the 2024 audited financial statements. The document is not a full annual report but a standalone audit-related report focusing on specific financial aspects related to non-operating funds and related party transactions. It is not an announcement or a brief summary but a detailed report with financial data and audit confirmation. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to specific financial matters, excluding full annual reports. The document length is under 5,000 characters but contains substantive financial data and audit opinion, so it is not a mere announcement or certification. Therefore, the correct classification is AR with high confidence.
2025-04-21 Chinese
关于回购注销部分限制性股票减资通知债权人的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement by the company regarding the repurchase and cancellation of part of its restricted stock, which leads to a reduction in registered capital. It includes a notification to creditors about the capital reduction and instructions for debt claims. The document is a formal notice to stakeholders about a capital change event, not a financial report or detailed management discussion. It does not contain financial statements or detailed financial analysis but rather informs about a corporate action affecting share capital and related creditor rights. Therefore, it fits the category of Share Issue/Capital Change announcements.
2025-04-21 Chinese
独立董事2024年度述职报告（吴乔）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2024 Annual Work Report" for Xiamen Aide Biomedical Technology Co., Ltd. It is a detailed report by an independent director summarizing their duties, attendance, and activities during the 2024 term. The content includes the director's background, attendance at board meetings, review of financial reports (notably the 2024 Q3 report), and compliance with regulations. It is not a full annual report or financial statement but a management-related report focusing on governance and director duties. It does not announce voting results, dividends, or capital changes, nor is it a transcript or legal proceeding. The document is a management report detailing the independent director's activities and oversight during the year, fitting the Board/Management Information (MANG) category best.
2025-04-21 Chinese
关于回购注销2023年限制性股票激励计划部分限制性股票的公告
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from a company regarding the repurchase and cancellation of restricted stock under a 2023 restricted stock incentive plan. It details the number of shares repurchased, the price, the reasons for repurchase (such as employees leaving or failing performance targets), approvals from board and supervisory meetings, legal opinions, and the impact on share structure. The document is focused on share repurchase related to stock incentives, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive details about the transaction itself. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or cancellations of its own shares.
2025-04-21 Chinese
关于2024年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement from a company regarding its 2024 annual profit distribution plan, including details on cash dividends per share, total dividend amount, and related financial figures. It references the approval by the board and supervisory committee and states that the plan will be submitted to the shareholders' meeting for approval. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution details. It is not a full annual report, earnings release, or interim report. The document is an announcement of the dividend amount and payment plan for the year 2024, which fits the definition of a Notice of Dividend Amount (DIV). The document length is short (2202 characters), and it is not merely announcing the publication of a report but providing the dividend plan itself. Therefore, the appropriate classification is DIV with high confidence.
2025-04-21 Chinese
董事会对独董独立性评估的专项意见
Board/Management Information Classification · 95% confidence The document is a special opinion from the board regarding the independence evaluation of independent directors, referencing regulatory rules about independent directors and their independence. It does not contain financial data, audit results, or report financial performance. It is a governance-related document focused on board and director matters. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2025-04-21 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.